GUTS Deadline Alert: SueWallSt Reminds Fractyl Health, Inc. (GUTS) Investors of Securities Class Action Deadline on October 20, 2026 - GUTS

Published October 8, 2026

$4.23

-6.42%

Event

Read full article on prnewswire.com →

About Fractyl Health, Inc.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Stock Price

$1.55

Price Change

-2.61%

More from GUTS

Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript - GUTS

October 16, 2026

GUTS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026 - GUTS

October 14, 2026

Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action - GUTS

October 12, 2026

GUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm - GUTS

October 7, 2026

Exchange Mix — Recent GUTS Events

NASDAQ

100%

NYSE

AMEX

OTC